Short answer
Regeneron Pharmaceuticals (REGN) filed its Q1 2026 10-Q quarterly report on Apr 29, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3.6B (up 19.0% year over year) with net income of $727M.
Q1 2026 key financials · XBRL
- Revenue
- $3.6B
- +19.0% YoY
- Net income
- $727M
- −10.1% YoY
- Operating margin
- 17.8%
- EPS (diluted)
- $6.75
- −7.2% YoY
Source: XBRL data from the Regeneron Pharmaceuticals (REGN) Q1 2026 10-Q on SEC EDGAR. USD.
Regeneron Pharmaceuticals Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3,605.4M, up 19% YoY from $3,028.7M
- Net income $727.2M vs $808.7M YoY; diluted EPS $6.75 vs $7.27
- Best product Dupixent sales $4,880.1M, up 33% YoY
- Worst product EYLEA sales $869.3M, down 40% YoY
- Outlook: EYLEA HD PFS regulatory decision anticipated during Q2 2026; pricing commitments and tariff protection through January 2029
Risk Factors
- Newly intensified biosimilar risk: additional EYLEA biosimilars expected to launch in the U.S. in second half of 2026
- EYLEA U.S. sales decline: net product sales fell 36% year over year amid competitive pressures
- Revenue concentration: EYLEA HD and EYLEA represented 26% of total revenue in Q1 2026
- EYLEA HD transition: U.S. sales comprised 50% of aggregate EYLEA franchise sales
- Regulatory exposure: FDA-approved EYLEA biosimilars already include one U.S. commercial launch
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Regeneron Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.